Although CDH21, LDH22, NCOR123 and other mutant genes are new biomarkers in HCC subtype classification24,25, identification of gene mutations that affect recurrence is complex but will have clinical significance. This evidence concerns the gene PCDHGA12 and hepatocellular carcinoma.